Dolor en el herpes zósterprevención y tratamiento

  1. G. Calvo-Mosquera 1
  2. A. González-Cal 1
  3. D. Calvo-Rodríguez 2
  4. C.Y. Primucci 1
  5. P. Plamenov-Dipchikov 1
  1. 1 Centro de Salud de Serantes, Ferrol, España
  2. 2 Hospital General de Asturias, Oviedo, España
Journal:
Semergen: revista española de medicina de familia

ISSN: 1138-3593

Year of publication: 2017

Issue: 4

Pages: 318-327

Type: Article

DOI: 10.1016/J.SEMERG.2016.02.001 DIALNET GOOGLE SCHOLAR

More publications in: Semergen: revista española de medicina de familia

Abstract

Shingles is a painful rash that results from reactivation of latent varicella-zoster virus in the dorsal root ganglia or cranial nerves. In this article an update is presented on the prevention and pharmacological treatment of the secondary pain from the virus infection. The most effective way to prevent post-herpetic neuralgia and its consequences is the prevention of herpes itself. A live attenuated vaccine (the Oka strain varicella zoster virus) has been available for several years, and is approved in adults aged 50 years old. Although this vaccine has shown to be effective against herpes zoster and post-herpetic neuralgia, its effectiveness decreases with age and is contraindicated in patients with some form of immunosuppression. Today the recombinant vaccines provide an alternative, and may be administered to immunocompromised persons.

Data source: Dialnet